Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study

BACKGROUND: Fingolimod is a sphingosine 1-phosphate receptor modulator approved for relapsing MS. Long-term effects on the immunological profile are not fully understood. OBJECTIVE: Investigate fingolimod's temporal effects on immune cell subsets, and safety outcomes. METHODS: In FLUENT, a 12-m...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao-Draayer, Yang, Cohen, Jeffrey A, Bar-Or, Amit, Han, May H, Singer, Barry, Williams, Ian M, Meng, Xiangyi, Elam, Chelsea, Weiss, Jamie L, Cox, Gina Mavrikis, Ziehn, Marina, Cree, Bruce AC
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346260/
https://www.ncbi.nlm.nih.gov/pubmed/35936922
http://dx.doi.org/10.1177/20552173221115023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346260/
https://www.ncbi.nlm.nih.gov/pubmed/35936922
http://dx.doi.org/10.1177/20552173221115023

Ejemplares similares